argenx reports positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositisAug 17Clinical readoutargenxefgartigimod
Halozyme posts record Q2 2026, raises full-year guidance on royalty growthAug 6Quarterly updateHalozyme Therapeutics
Sign inSign in